Fetuin-mineral complex reflects extraosseous calcification stress in CKD.
Fetuin-A is an important inhibitor of extraosseous calcification, but some of the studies that used ELISAs did not identify a significant relationship between serum fetuin-A levels and vascular calcification in patients with chronic kidney disease (CKD). Here, we used centrifugation to separate a fetuin-mineral complex (FMC) composed of fetuin-A, fibrinogen, fibronectin-1, and calcium from the serum of hemodialysis patients. In addition, we analyzed serum fetuin-A levels of 73 patients with diabetes and CKD (predialysis) after centrifugation. Fetuin-A concentrations were significantly lower in supernatants than in serum from patients at any stage of CKD, indicating systemic circulation of FMC in these patients. With greater severity of CKD, the contribution of FMC to total fetuin-A increased. Despite the absence of a correlation between serum fetuin-A and coronary artery calcification scores (CACS), supernatant fetuin-A negatively correlated with CACS and the extent to which centrifugation reduced fetuin-A (reduction ratio [RR]) positively correlated with CACS. In a longitudinal study of 12 hemodialysis patients with secondary hyperparathyroidism, parathyroidectomy and cinacalcet therapy each significantly reduced the RR without changing supernatant fetuin-A levels after 1 month, suggesting a reduction in FMC. Moreover, the magnitude of cinacalcet-induced reduction in parathyroid hormone correlated with the decrease in RR but not with changes in serum or supernatant fetuin-A. These data suggest that a quantitative measure of FMC, not supernatant or serum fetuin-A as measured in previous studies, reflects extraosseous calcification stress.
Hamano
Takayuki
T
Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. hamatea@medone.med.osaka-u.ac.jp
Matsui
Isao
I
Mikami
Satoshi
S
Tomida
Kodo
K
Fujii
Naohiko
N
Imai
Enyu
E
Rakugi
Hiromi
H
Isaka
Yoshitaka
Y
D000368:Aged; D015415:Biomarkers / Q000378:metabolism; D001798:Blood Proteins / Q000378:metabolism*; D002114:Calcinosis / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism*; D016022:Case-Control Studies; D002908:Chronic Disease; D000069449:Cinacalcet; D003324:Coronary Artery Disease / Q000378:metabolism; D005260:Female; D005340:Fibrinogen / Q000378:metabolism*; D005353:Fibronectins / Q000378:metabolism*; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy / Q000378:metabolism; D007674:Kidney Diseases / Q000150:complications / Q000378:metabolism* / Q000628:therapy; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use; D006435:Renal Dialysis; D012720:Severity of Illness Index; D060749:alpha-2-HS-Glycoprotein
C556354:AHSG protein, human; D015415:Biomarkers; D001798:Blood Proteins; D005353:Fibronectins; D009281:Naphthalenes; D060749:alpha-2-HS-Glycoprotein; D005340:Fibrinogen; D002118:Calcium; D000069449:Cinacalcet